108 related articles for article (PubMed ID: 9815773)
41. Prognostic significance of a combination of thymidylate synthase and dihydropyrimidine dehydrogenase activities in grades 1 and 2 superficial bladder cancer.
Mizutani Y; Wada H; Yoshida O; Fukushima M; Bonavida B; Kawauchi A; Miki T
Oncol Rep; 2002; 9(2):289-92. PubMed ID: 11836594
[TBL] [Abstract][Full Text] [Related]
42. Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer.
Takihana Y; Tsuchida T; Fukasawa M; Araki I; Tanabe N; Takeda M
Int J Urol; 2006 Apr; 13(4):401-8. PubMed ID: 16734859
[TBL] [Abstract][Full Text] [Related]
43. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
44. Assessment of the VEGF, bFGF, aFGF and IL8 angiogenic activity in urinary bladder carcinoma, using the mice cutaneous angiogenesis test.
Rogala E; Skopińska-Rózewska E; Sommer E; Pastewka K; Chorostowska-Wynimko J; Sokolnicka I; Kazoń M
Anticancer Res; 2001; 21(6B):4259-63. PubMed ID: 11908679
[TBL] [Abstract][Full Text] [Related]
45. Pharmacodynamics of doxorubicin in human bladder tumors.
Gan Y; Wientjes MG; Badalament RA; Au JL
Clin Cancer Res; 1996 Aug; 2(8):1275-83. PubMed ID: 9816297
[TBL] [Abstract][Full Text] [Related]
46. Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo.
Tsukagoshi S; Saga Y; Suzuki N; Fujioka A; Nakagawa F; Fukushima M; Suzuki M
Int J Oncol; 2003 May; 22(5):961-7. PubMed ID: 12684660
[TBL] [Abstract][Full Text] [Related]
47. Potential for molecular-targeted therapy targeting human epidermal growth factor receptor-2 for invasive bladder cancer.
Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Inoue Y; Noguchi H; Honda N
Oncol Rep; 2007 Jul; 18(1):3-7. PubMed ID: 17549338
[TBL] [Abstract][Full Text] [Related]
48. Thymidine phosphorylase and dihydropyrimidine dehydrogenase in bladder cancer.
Iizumi T; Hariu K; Sato M; Sato S; Shimizu H; Tomomasa H; Umeda T
Urol Int; 2002; 68(2):122-5. PubMed ID: 11834904
[TBL] [Abstract][Full Text] [Related]
49. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
50. De novo muscle invasive bladder cancer: is there a change in trend?
Vaidya A; Soloway MS; Hawke C; Tiguert R; Civantos F
J Urol; 2001 Jan; 165(1):47-50; discussion 50. PubMed ID: 11125361
[TBL] [Abstract][Full Text] [Related]
51. Surgical factors in the treatment of superficial and invasive bladder cancer.
Herr HW
Urol Clin North Am; 2005 May; 32(2):157-64. PubMed ID: 15862613
[TBL] [Abstract][Full Text] [Related]
52. [Clinical prognostic factors in superficial cancer of the urinary bladder].
Busto Catañón L; Sánchez Merino JM; Picallo Sánchez JA; Gelabert Mas A
Arch Esp Urol; 2001 Mar; 54(2):131-8. PubMed ID: 11341116
[TBL] [Abstract][Full Text] [Related]
53. Novel invasive orthotopic bladder cancer model with high cathepsin B activity resembling human bladder cancer.
Lodillinsky C; Rodriguez V; Vauthay L; Sandes E; Casabé A; Eiján AM
J Urol; 2009 Aug; 182(2):749-55. PubMed ID: 19539312
[TBL] [Abstract][Full Text] [Related]
54. Expression of vascular endothelial growth factor in primary superficial bladder cancer.
Chow NH; Liu HS; Chan SH; Cheng HL; Tzai TS
Anticancer Res; 1999; 19(5C):4593-7. PubMed ID: 10650816
[TBL] [Abstract][Full Text] [Related]
55. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates.
Crew JP; O'Brien T; Bicknell R; Fuggle S; Cranston D; Harris AL
J Urol; 1999 Mar; 161(3):799-804. PubMed ID: 10022687
[TBL] [Abstract][Full Text] [Related]
56. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer.
Kawanishi H; Matsui Y; Ito M; Watanabe J; Takahashi T; Nishizawa K; Nishiyama H; Kamoto T; Mikami Y; Tanaka Y; Jung G; Akiyama H; Nobumasa H; Guilford P; Reeve A; Okuno Y; Tsujimoto G; Nakamura E; Ogawa O
Clin Cancer Res; 2008 May; 14(9):2579-87. PubMed ID: 18451219
[TBL] [Abstract][Full Text] [Related]
57. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
58. Distribution of DT-diaphorase and reduced nicotinamide adenine dinucleotide phosphate: cytochrome p450 oxidoreductase in bladder tissues and tumors.
Li D; Gan Y; Wientjes MG; Badalament RA; Au JL
J Urol; 2001 Dec; 166(6):2500-5. PubMed ID: 11696818
[TBL] [Abstract][Full Text] [Related]
59. A role of thymidine phosphorylase and P53 tissue protein expression in biology of endometrial cancer.
Mazurek A; Kuć P; Mazurek-Wadołkowska E; Laudański T
Neoplasma; 2008; 55(3):261-5. PubMed ID: 18348659
[TBL] [Abstract][Full Text] [Related]
60. [Mode of action of fluoropyrimidines, in relation to their clinical application].
Suga S; Kimura K; Kubo K; Aoyama H; Inukai N; Kato K; Horiuchi T; Sawada H; Yokoyama Y
Gan To Kagaku Ryoho; 1984 Nov; 11(11):2301-6. PubMed ID: 6497396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
